SGLT2 Inhibitors Versus GLP-1 Receptor Agonists for Kidney Outcomes

Clinical Editorial

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with type 2 diabetes.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Nonlinear association of sleep quality (PSQI) with type 2 diabetes prevalence in community chronic

Endocrinology • 21 Aug 2026

Med News TodayRelated by Conditiondiabetestype 2 diabetes

FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know

Infectious Disease • 23 Aug 2026

Ancestry-aware TWAS pinpoints tissue-specific genes at type 2 diabetes GWAS loci

Endocrinology • 22 Aug 2026

Med News TodayRelated by Conditiondiabetestype 2 diabetes

Urolithin A from Pomegranate Precursors May Improve Heart Relaxation in HFpEF Models

Cardiology • 22 Aug 2026

Werner Syndrome Presenting as Diabetes: Genetic Diagnosis Enables Precision Treatment

Pharmacology • 22 Aug 2026

Endocrine NewsRelated by Conditiondiabetestype 2 diabetes

Lila Dabill, PhD: Sarm1 Neural Knockout Links to Obesity Prevention — ENDO 2026 Rising Star Q&A